News & Perspective

Jul 13, 2011

Jul 13, 2011

Study: Adjuvanted H1N1 vaccines had little effect on GBS risk

(CIDRAP News) – A five-country study from Europe indicates that the use of adjuvanted vaccines against the pandemic H1N1 influenza virus probably did not increase the risk of Guillain-Barre syndrome (GBS), but the investigators could not firmly rule out a slightly greater chance of suffering the paralytic condition.

Aug 16, 2007

Aug 16, 2007

Glaxo sells more H5N1 vaccine to US, launches trial

(CIDRAP News) – The British pharmaceutical company GlaxoSmithKline (GSK) recently announced another major order of prepandemic H5N1 influenza vaccine from the US Department of Health and Human Services (HHS), along with plans to launch a North American clinical trial of the vaccine.

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation Gilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»